SLU-PP-332 side effects and risks

Reported side effects

• Sweating or feeling hot: community reports: Reported online; no measured incidence., moderate. Stop and seek assessment if overheating, weakness or confusion develops. (source)
• Fatigue or brain fog: community reports: Reported during higher dosing and after stopping; rates and cause unknown., moderate. Persistent or disabling symptoms need clinical assessment. (source)
• Trouble sleeping: community reports: No placebo controlled frequency estimate., moderate (source)
• Injection pain or irritation: Reported online; product and solvent contributions unknown., moderate. Hot, swollen or spreading redness needs urgent assessment. (source)
• Lightheadedness and glucose changes: Both high and low readings reported; one comment gave 2.6 mmol/L. No verified incidence., serious. Check glucose during symptoms; confusion or collapse needs emergency care. (source)
• Reduced libido: isolated high-dose report: One poster escalated to 500 mg/day orally; hormone injury was not confirmed., moderate (source)
• Menstrual or breast changes: isolated report: One female commenter; no hormone tests or causal confirmation., moderate (source)
• Nausea during multi-drug use: One tesamorelin combination report; cause uncertain., moderate (source)
• Infection or serious allergy from unregulated injections: General unapproved injection risk; no SLU PP 332 specific rate., serious (source)

Stop and get help if

• Throat or tongue swelling, wheeze or trouble breathing: Stop exposure and call emergency services now; use prescribed adrenaline if available.
• Chest pain with breathlessness, sweating or faintness: Stop and call emergency services now.
• Confusion, seizure, collapse or low glucose that does not recover: Get emergency help. Do not give food or drink to an unconscious person.
• A painful, hot, swollen injection site or spreading redness: Seek urgent same-day care; rapid breathing, faintness or severe illness needs emergency help.

Who should avoid it

• pregnant: Precaution: no pregnancy exposure, fetal safety or reproductive-toxicity data were found.
• breastfeeding: Precaution: transfer into milk and effects on a nursing infant are unknown.
• tryingToConceive: Precaution: fertility effects and a safe washout interval are unknown.
• under18: Precaution: no pediatric dosing or developmental safety studies were found.
• heartCondition: Human heart safety is unknown; a mouse heart-failure result cannot establish benefit or safety in people.
• uncontrolledBloodPressure: No human blood-pressure safety data. Heart-rate and faintness complaints appear in unverified reports.
• diabetes: Human glucose responses are unknown. Both higher and lower glucose have been reported online.
• kidneyDisease: Human clearance and dose adjustment are unknown; mouse kidney findings do not establish a kidney-safe dose.
• liverDisease: Human liver preparations break down the compound; exposure and dose adjustment with liver disease are unknown.
• activeCancer: No cancer safety studies in people were found. Effects on cell energy pathways do not establish cancer safety.
• surgeryPlanned: Tell the anesthesia team about use and all solvents. No evidence-based time to stop before surgery is known.
• testedAthlete: Prohibited at all times. Not being named in the 2026 list does not make an unapproved drug permitted.
• other: A previous serious allergic reaction to this product or its solvent should stop repeat exposure.

Interactions

• Insulin: Insulin can cause low glucose. Added SLU-PP-332 effects and insulin-adjustment rules have not been studied in people.
• Sulfonylureas: These drugs can cause low glucose. Added effects and dose-adjustment rules with SLU-PP-332 have not been studied in people.
• GLP-1 drugs and retatrutide: No human combination trial found. Users report lightheadedness and variable glucose during multi-drug use.
• Other ERR agonists: Same-target combinations have no human safety data. SLU-PP-915 is a different compound, not an oral version of SLU-PP-332.
• BAM15 and other experimental metabolic drugs: Online combinations add unstudied metabolic effects; no protective or safe stacking schedule is known.
• Piperine absorption boosters: Oil/piperine mixtures are proposed online to alter exposure. Neither absorption nor interaction risk has been measured in people.
• Warfarin and other anticoagulants: No interaction data exist. This is an uncertainty screen for drugs where exposure changes or injection bleeding matter, not a proven drug interaction.

Product quality risks

• Health Canada warns that unauthorized injectable drugs have not been assessed for safety, efficacy or quality. This is general product-risk evidence.
• Wrong identity, wrong amount, microbial contamination and unsafe excipients are risks of unauthorized drugs; their frequency for SLU-PP-332 is unknown.
• No independent retail-product survey or SLU-PP-332-specific poison-center dataset was found. Vendor certificates are not a substitute.
• Powder purity does not establish dose per capsule/vial, solvent safety, sterility or endotoxin levels.
• Cloudy or settled mixtures can have uncertain dose uniformity. A clear appearance also cannot prove injection quality.